Table 2 Demographic characteristics of included studies for the management of hypertension in neurocritical patients.
Study ID, NOS | Study design | Clev details | Control details | Total cohort | Diagnosis | Target BP | Hypo tension | Tachy cardia | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clev | Control | ICH | AIS | SAH | SDH | Others | |||||||
Borrell-Vega 2020, 7 | Retro | 10.8 + 9.1 mg/h | Nicardipine; max. 15 mg/h | 12 | 12 | 7 | 1 | 3 | – | 1 | SBP < 140 mm Hg for ICH, < 160 mm Hg for SAH and < 180 mm Hg for IS | SBP < 90 mmHg | > 100 bpm |
Finger 2016, 7 | Retro | 3 (1.5–8) mg/h | Nicardipine, 5 (4–7) mg/h | 19 | 38 | 24 | 6 | – | – | 27 | Not defined | SBP < 100 mmHg | > 120 bpm |
Rosenfeldt 2018, 8 | Retro | 2 mg/h | Nicardipine; n.r | 59 | 60 | 37 | 1 | 5 | 73 | 20 | Not defined | SBP < 100 mmHg | > 120 bpm |
Rodriguez 2022, 8 | Retro | 1 ± 1 mg/h | None | 33 | – | 3 | 6 | 4 | – | 11 | SBP maintained for more than 75% of infusion length and no need of rescue treatment with different intravenous antihypertensive drugs | SBP < 80 mmHg for at least 5 min within 1 h of infusion begin | Not defined |
Allison 2017, 7 | Retro | 2 mg/h; doubling the dose every 90 s until a rate of 12 mg/h was reached, and then increasing by 4 mg/h increments to a maximum dose of 32 mg/h | Nicardipine; initially 5 mg/h titrated per 15 min to a maximum of 15 mg/h | 70 | 140 | 133 | 77 | – | – | – | SBP < 180 mmHg for AIS or < 150 mmHg for ICH | SBP < 91 mmHg | Not defined |
